Diagnostic value of MSCT plain scan and dual-phase enhanced scan in thymic adenocarcinoma

• Main Author: Bing Liu
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2019-04-01
• Series: Journal of Hainan Medical University
• Online Access: http://www.hnykdxxb.com/PDF/201907/15.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To evaluate the value of MSCT plain scan and enhanced CT in the diagnosis of thymic adenocarcinoma. Methods: From May 2013 to June 2018, 37 cases of MSCT plain scan and dual-phase enhanced scan of thymic adenocarcinoma were retrospectively analyzed. The location, shape, size, density (CT value), enhanced features, peripheral invasion and mediastinal lymph node metastasis of the lesions were observed. Results: All 37 cases of thymic adenocarcinoma were diagnosed by CT before operation, and all cases were diagnosed by pathology after operation as malignant tumors,including 28 cases of thoracic adenocarcinoma and 9 cases of invasive thymoma. All 28 cases of thymic adenocarcinoma were single lesion of anterior superior mediastinum. The maximum cross-section was located in the midline in 7 cases and on the mediastinal side in 21 cases with significant difference (P<0.05). All lesions were irregular lobulated. The minimum diameter of lesions was 2.1 cm and the maximum diameter was 8.6 cm. Soft tissue density was dominant in the solid part. All cases of thymic adenocarcinoma showed inhomogeneous, moderate and severe enhancement in the arterial and venous phase after enhancement. The degree of enhancement in the venous phase was higher than that in the arterial phase, and there was no enhancement in the irregular liquefied necrosis area. 26 cases had necrotic lesions, 21 cases had mediastinal lymph node metastasis, and 8 cases had invasion of adjacent pleura. 19 cases had mediastinal vessels and 0 cases had distant pleural metastases. Conclusion: MSCT plain scan combined with dual-phase enhanced CT is helpful to display the details and metastasis of thymic adenocarcinoma, improve the coincidence rate of CT diagnosis and pathological diagnosis, and reduce the misdiagnosis rate. To provide help for clinical diagnosis and treatment of thymic adenocarcinoma.